Promising Results from Spinogenix's Phase 2 Trial of Tazbentetol for Schizophrenia Show Safety and Efficacy

Spinogenix Unveils Exciting Developments in Schizophrenia Treatment

In a groundbreaking presentation at the Schizophrenia International Research Society (SIRS) 2026 Annual Congress, Spinogenix, Inc., a clinical-stage biopharmaceutical enterprise known for its innovative therapies, provided promising interim results from its Phase 2 clinical trial of tazbentetol. This unique investigational drug aims to tackle schizophrenia, a complex and often debilitating psychiatric illness that manifests through a combination of positive, negative, and cognitive symptoms.

Schizophrenia represents a significant challenge within mental health, affecting countless individuals globally. The hallmark symptoms include hallucinations and delusions (positive symptoms), social withdrawal and lack of motivation (negative symptoms), and cognitive deficits such as issues with memory and attention. The need for effective treatment avenues is dire, as existing options offer limited hope for complete symptom resolution.

Tazbentetol emerges as a first-in-class synaptic regenerative therapy, designed to address the interplay of all three symptom domains associated with schizophrenia. In this rigorous, randomized, double-blind, placebo-controlled trial (NCT06442462), 32 adult participants diagnosed with schizophrenia were enrolled to evaluate the safety, efficacy, and pharmacodynamics of the medication. Participants were administered either a daily oral dose of 300mg of tazbentetol or a placebo over a six-week period.

Positive Initial Findings

The interim analysis, which included data from 16 participants, demonstrated noteworthy trends suggesting potential improvements in both positive and negative symptoms. Notably, there were positive shifts in brain activity associated with schizophrenia, as evidenced by EEG evaluations. This is a vital indicator that signals the drug's mechanism of action might be working effectively.

Favorable Safety Profile: One of the most encouraging aspects of tazbentetol is its safety profile. The interim data revealed no severe adverse events related to the drug, indicating it was well-tolerated among participants.

Overall Symptom Severity Reduction: Patients receiving tazbentetol experienced a more substantial reduction in their PANSS (Positive and Negative Syndrome Scale) scores compared to those who received the placebo. Specifically, the mean change from baseline demonstrated a significant difference, with the tazbentetol group showing a reduction of -11.1 compared to -5.5 for placebo, equating to a -5.6 point difference at Day 71 of the treatment.

Improvements in Positive and Negative Symptoms: The study revealed significant improvements among participants receiving tazbentetol in the PANSS positive and negative sub-scale scores. Specifically, the tazbentetol group had a mean change of -2.5 in the positive subscale and -1.8 in the negative subscale, compared to lower improvements in the placebo group.

Insight from EEG Biomarkers

The trial also utilized EEG metrics, revealing significant changes associated with treatment: tazbentetol showcased improvements in gamma and alpha band power abnormalities related to schizophrenia in various brain regions. Specifically, these changes were statistically significant, showing promise for the drug's mechanism of affecting cortical activity.

Dr. David Walling, the Chief Clinical Officer at CenExel and Principal Investigator of the trial, highlighted these results as potentially revolutionary: "This study underscores the important connections between synapse loss and schizophrenia symptoms, suggesting that regeneration could lead to more comprehensive treatment outcomes."

Dr. Stella Sarraf, CEO and Founder of Spinogenix, expressed her optimism regarding these findings: "We are encouraged to see how tazbentetol may fill critical gaps in the treatment of schizophrenia. The drug's potential to shift our approach from merely managing symptoms to addressing underlying synaptic dysfunction is especially exciting."

A New Horizon in Neuropsychiatric Treatment

Spinogenix is dedicated to transforming the treatment landscape for various neurodegenerative and neuropsychiatric_conditions, focusing on restoring synapses and reversing their degeneration. Tazbentetol, previously referred to as SPG302, aims to enhance synaptic health and address broader implications in conditions like Alzheimer’s and ALS, alongside schizophrenia.

As the medical community awaits further results from ongoing phases of this trial, the preliminary evidence surrounding tazbentetol sets a promising tone for future developments—where effective therapies for schizophrenia and other neuropsychiatric disorders could finally become a reality for millions.

For more information about Spinogenix and its innovative approaches to neuropsychiatric treatment, visit Spinogenix.com.